Results 221 to 230 of about 451,388 (320)

CLA-1 is an 85-kD plasma membrane glycoprotein that acts as a high-affinity receptor for both native (HDL, LDL, and VLDL) and modified (OxLDL and AcLDL) lipoproteins.

Arteriosclerosis, Thrombosis and Vascular Biology, 1997
D. Calvo, D. Gómez-Coronado, M. A. Lasunción, M. Vega   +3 more
semanticscholar   +1 more source

Psychiatric Safety of Tirzepatide in People With Obesity and No Known Major Psychopathology: A Post Hoc Analysis of SURMOUNT

Obesity, EarlyView.
ABSTRACT Objective This post hoc analysis assessed psychiatric changes with tirzepatide in adults with obesity, without known major psychopathology, from SURMOUNT‐1, SURMOUNT‐2, and SURMOUNT‐3. Methods In participants (N = 4056) treated with tirzepatide (5/10/15 mg or maximum tolerated dose 10/15 mg) versus placebo, depressive symptoms and suicidal ...
Thomas A. Wadden, Maria A. Oquendo, Robert F. Kushner, Dachuang Cao, Chrisanthi A. Karanikas, Afton Kechter, Madhumita A. Murphy   +6 more
wiley   +1 more source

Comparison of Lipid Measurements by Clinical Chemistry and NMR Spectroscopy. [PDF]

Diagnostics (Basel)
Tekin N, Saral NY, Toker A, Şahin F, Baykal AT, Serteser M.   +5 more
europepmc   +1 more source

Efficacy and Safety of Tirzepatide in Japanese Participants With Obesity: A Subpopulation Analysis of the SURMOUNT‐1 Trial

Obesity, EarlyView.
ABSTRACT Objective This prespecified subpopulation analysis aimed to assess the efficacy and safety of once‐weekly tirzepatide versus placebo alongside lifestyle intervention in Japanese adults with obesity or overweight. Methods Data from 102 Japanese adults in the SURMOUNT‐1 trial with BMI ≥ 30 kg/m2 or ≥ 27 kg/m2 and ≥ 1 weight‐related comorbidity ...
Yasushi Ishigaki, Masamichi Yamada, Tomotaka Shingaki, Tomonori Oura, Iichiro Shimomura   +4 more
wiley   +1 more source

The Role of Lipid Alteration in Multiple Sclerosis. [PDF]

Int J Mol Sci
Damiza-Detmer A, Pawełczyk M, Głąbiński A.   +2 more
europepmc   +1 more source

Detergent-mediated phospholipidation of plasma lipoproteins increases HDL cholesterophilicity and cholesterol efflux via SR-BI.

Biochemistry, 2006
H. Pownall
semanticscholar   +1 more source

T‐Cell Signaling Pathways, Including Exhaustion, Predominate in Unhealthy Visceral and Subcutaneous Adipose Tissues

Obesity, EarlyView.
ABSTRACT Objective Obesity is an imperfect correlate of metabolic health. Visceral adipose tissue (VAT) characteristics are considered determinants of poor health and subcutaneous adipose tissue (SAT) considered protective. There is a gap in knowledge regarding shared vs.
Sobha Puppala, Alyssa R. Hamann, Christina M. Stevens, Alistaire Ruggiero, Laura A. Cox, Kylie Kavanagh   +5 more
wiley   +1 more source

Targeting Triglycerides in Cardiovascular Disease Prevention: Evidence, Mechanisms, and Emerging Therapies. [PDF]

Curr Cardiol Rep
Alam U, Mathai SV, Filtz A, Kuno T, Badimon JJ, Sniderman AD, Virani SS, Toth PP, Shapiro MD, Lavie CJ, Bhatt DL, Slipczuk L.   +11 more
europepmc   +1 more source

Prevalence of non‐alcoholic fatty liver disease and its association with different combinations of weight status and metabolic abnormalities in children aged 6–18 years

Pediatric Investigation, EarlyView.
Children with non‐overweight combined with metabolic risk factors might increase the risk of non‐alcoholic fatty liver disease (NAFLD). These findings suggest that overweight and obesity should not be the sole criterion for NAFLD screening in children. In particular, more attention should be given to non‐overweight combined with metabolic abnormalities
Peiyu Ye, Luting Peng, Liwang Gao, Xiaonan Li, Qin Liu, Pei Xiao, Liang Wang, Xiaoyan Shi, Jun Ma, Yanhui Dong, Dongling Dai, Qinghua Yang, Xinchun Chen, Xin Fan, Naijun Wan, Jin Zhang, Bin Li, Lin Zhou, Guangsheng Wu, Lin Yang, Yan He, Yinkun Yan, Jie Mi   +22 more
wiley   +1 more source

Metabolomic biomarkers of psychotic conversion in ultra-high-risk subjects: a pilot study. [PDF]

Transl Psychiatry
Avella MT, Bertho G, Giraud N, Kébir O, Caradeuc C, Labad J, Papiol S, Schulze TG, Krebs MO, Chaumette B, Frajerman A.   +10 more
europepmc   +1 more source